

THAIRE LIFE ASSURANCE PUBLIC COMPANY LIMITED

# 3Q 2021 and 9M 2021

Analyst Meeting

16 November 2021

## **Disclaimer**

The information of this presentation is the intellectual property of "Thaire Life Assurance Public Company Limited" (THREL). You may not reuse, republish or reprint or duplicate such information without written consent of THREL.

All information is solely for reinsurance purpose. While the information of this presentation has been verified to the best of abilities, THREL cannot guarantee that there are no mistakes, errors.

THREL reserves the right to change the information at any given time, of which you will be promptly updated. If you would like to ensure the up-to-date information, please <u>visit our website : www.thairelife.co.th</u>



# Agenda

## **1** About THREL & Business Overview

## **2** Thailand Life Insurance Market

- **3** Financial Performance
- **4** Outlook & Strategic Plan



# **About THREL & Business Overview**






## **THREL** at a glance

- THREL is only local life reinsurance company in Thailand
- THREL established in 2000 and listed in the SET since October 9, 2013
- Though all 22 domestic life insurance companies are customer of THREL

#### **Thailand Life Reinsurance Market Share in 2020**










## **THREL Business Profile Update**



THREL has been listed as Thailand Sustainability Investment 2021.



## What THREL do?



- We are only one Reinsurer with local service. THREL มีความเข้าใจตลาดและให้บริการได้รวดเร็ว
- We maintain CAR >300% which equivalent to Credit rating AAA of OIC guideline.


ลูกค้าจะมีต้นทุนที่ถูกกว่าหากใช้บริการกับ THREL

• We gain market share 15-20% in Thai market. THREL เป็นบริษัทชั้นนำในตลาดประเทศไทย



Group

## **Characteristics of THREL**




# **Thailand Life Insurance Market**



## Life Insurance Market Trends in 2021F

(Unit : Million Baht)



#### -3.4% 2.3% Single premium mainly from investment linked 439,182 444,441 429,382 product 54,320 -26% 40.060 39% 55,731 First year premium 75,764 -2% 74,502 -10% 67,360 decreased mainly from endowment product 314,357 0% 314,820 0% 316,092 Renewal premium increased by Investment linked product Rider products eg, Jan-Sep Jan-Sep Jan-Sep health rider, CI rider 2019 2020 2021 Key Challenge factor & **Key Support factor** Tax measures Economic downturn Deposit protection Impact of COVID-19 Vaccine COVID-19 Low interest rate Health trend 2021 Personalization demand trend การลดคุ้มครองเงินฝาก 10


Gross Premium Jan - Sep

- Trend in 2021 Decrease Focus mo Health &
  - Decrease in sum insured of primary life insurance due to the purchasing power of consumers. Focus more on Life protection product instead of endowment product. Health & CI is more popular.

## **Reinsurance premium**

(Unit : Mil Baht)

REL



- RI premium shows the CAGR (2017-2020) is 16.5%.
- In 2020, FYP's RI premium have a risen by 35% from increasing of the ordinary life product is amount +1,084 MB, growth 94% from 2019. And RYP's RI premium have a risen by 19% from increasing of the ordinary life product and health & CI rider is amount +1,060 MB and +681 MB, respectively.

## **Thailand Insurance Market Vs THREL**





#### Key factor

1. Covid-19

2. Low Interest Rate

- 3. Slowdown from Banking Sector
  - Lending e.g. SMEs
  - Loan to value Policy
  - NPL monitoring for TFRS#9
- 4. New Regulations
  - PDPA
  - IFRS#17

# **3Q 2021 and 9M 2021** Financial Performance



## Financial Performance 3Q and 9M 2021

Unit: Million Baht	3Q20	3Q21	ΥοΥ	9M20	9M21	YoY
Gross Written Premiums	581	842	45%	1,826	2,292	26%
Net Earned Premium	593	777	31%	1,702	2,014	18%
Change in Long-term policy reserve	7	(4)	-167%	33	0	-99%
Unexpired risk reserves	0	12	100%	(10)	12	226%
Net Claims	384	552	44%	1,111	1,403	26%
Net Commission	146	167	15%	433	446	3%
Earning on UWD - bef expenses	57	50	-11%	134	152	14%
Total Expenses	33	38	12%	97	109	12%
Earning on UWD - after expenses	24	13	-45%	37	44	18%
Net investment income and other	20	11	-46%	45	55	21%
Profit before tax	44	24	-45%	82	99	20%
Income Tax Expenses	6	3	-49%	10	13	32%
Net Profit	38	21	-45%	73	86	18%
EPS (Bt)	0.06	0.03	///	0.12	0.14	6/1
Loss Ratio	65.4%	71.7%		66.2%	70.1%	
Commission Ratio	24.9%	21.7%		25.8%	22.3%	
Expenses Ratio	5.8%	4.5%		5.4%	4.8%	
Combined Ratio	96.1%	97.9%		97.4%	97.2%	

#### <u>3Q/2021</u>

#### Premium: growth 45% ,or +261 MB

- Premium growth from
  - Short-term business +271 MB mainly from Group due to new contracts.
  - Long-term business -11 MB mainly from credit life due to economic slowdown and bank delay lending.

#### Claim: +44%, or +168 MB

- Group claim increased related to the premium growth, especially from Group health.
- Claim reserve for COVID approximately 100 MB
- Credit life claim increased from major loss.

#### Investment -46%, or -9 MB

• Declined mainly due to impairment (15 MB).

#### <u>9M/2021</u>

#### Premium: growth 26% ,or +466 MB

- Premium growth from
  - Short-term business +525 MB
  - Long-term business -59 MB

#### Claim: +26%, or +292 MB

• Group claim increased related to the premium growth, especially from Group health and Group life.

#### Investment


• Overall increase mainly from Stock market recovery and gain from sale of securities.

## Financial Performance 3Q and 9M – Excl.Claim Covid 100 MB

Unit: Million Baht

					Excl.C	ovid				Excl.Covid	
		3Q20	3Q21	ΥοΥ	3Q21	ΥοΥ	9M20	9M21	ΥοΥ	9M21	ΥοΥ
	Gross Written Premiums	581	842	45%	842	45%	1,826	2,292	26%	2,292	26%
	Net Earned Premium	593	777	31%	777	31%	1,702	2,014	18%	2,014	18%
	Change in Long-term policy reserve	7	(4)	-167%	(4)	-167%	33	0	-99%	0	-99%
	Unexpired risk reserves	0	12	100%	12	100%	(10)	12	226%	12	226%
	Net Claims	384	552	44%	452	18%	1,111	1,403	26%	1,303	17%
	Net Commission	146	167	15%	167	15%	433	446	3%	446	3%
	Earning on UWD - bef expenses	57	50	-11%	150	164%	134	152	14%	252	88%
	Total Expenses	33	38	12%	38	12%	97	109	12%	109	12%
	Earning on UWD - after expenses	24	13	-45%	113	380%	37	44	18%	144	289%
	Net investment income and other	20	11	-46%	11	-46%	45	55	21%	55	21%
	Profit before tax	44	24	-45%	124	182%	82	99	20%	199	141%
	Income Tax Expenses	6	3	-49%	3	-49%	10	13	32%	13	32%
	Net Profit	38	21	-45%	121	220%	73	86	18%	186	156%
	EPS (Bt)	0.06	0.03		0.20	/ / /	0.12	0.14		0.31	
	Loss Ratio	65.4%	71.7%		58.7%		66.2%	70.1%		65.1%	
	Commission Ratio	24.9%	21.7%		21.7%		25.8%	22.3%		22.3%	
	Expenses Ratio	5.8%	4.5%		4.5%		5.4%	4.8%		4.8%	
EL	Combined Ratio	96.1%	97.9%		84.9%		97.4%	97.2%		92.2%	

### **THREL Product Mix 9M2021 Vs 9M2020**





## **Product Portfolio by Character of business (Con VS Non-con)**


THREL

Million E	Baht			Tota	l Premiur	ms										
				+2	6%			9M20			9M21			%		
Short-t	term				2,2	292		Con	Non	Total	Con	Non	Total	Con	Non	Total
Long-te	erm						Premium	950	876	1,826	1,184	1,107	2,292	25%	26%	<b>26%</b>
							%Contribution	<b>52%</b>	48%	100%	<b>52%</b>	48%	<b>100%</b>			
							Earned Premiums	920	792	1,711	989	1,013	2,002	8%	28%	17%
				1,8	326		Life Policy Reserve	0	33	33	0	0	0	0%	-100%	-100%
							Net Claim	595	516	1,111	698	705	1,403	17%	37%	<b>26%</b>
Conve	ntional	Non-conve	entional				Net Commission	268	165	433	235	211	446	-12%	28%	3%
	+25%				1,5	570	Profit fr UWD	57	78	134	56	97	152	-2%	24%	13%
			+26%	1,0	37											
	1,184		1,107	-)0			Loss Ratio	64.7%	68.1%	66.2%	70.6%	69.7%	<b>70.1%</b>			
950							Comission Ratio	29.2%	21.7%	25.8%	23.7%	20.9%	22.3%			
550		876					Expenses Ratio	5.4%	5.3%	5.4%	4.8%	4.7%	4.8%			
	750						Combined Ratio	99.2%	95.1%	97.4%	99.1%	95.3%	97.2%			
463			820				Non conventional hu	sinoss hi	abor 26%	which	ontribut	tod to to	tal com	2201/06	ort at 19	20/
		574					<ul> <li>Non-conventional business higher 26% which contributed to total company port at 48%</li> <li>Premium growth from both Group and Health product</li> </ul>									
				78	39 <del>7</del> -	22	Commission ratio		•				6 to 20.9	%		
488	105					22	U/W profit impro	ved from	78 MB 1	:o 97 MB	or +24%	, 5				
400	435	302	287				Conventional Invite	- hishau	250/	ab as utu	:ht.a.d.t.			we with a th	<b>F3</b> 0/	
			1				<ul> <li>Conventional business higher 25% which contributed to total company port at 52%</li> <li>COVID-19 impact the new lending activity which directly impacted to credit life product</li> </ul>									
9M20	9M21	1 9M20 9M21 9M20 9M				9M21 • Premium growth from Group health (New contract)										
							• U/W profit slight		-	-	-					
																17

Confidential – For Internal Use Only

## **Investment asset & income**

Unit: Million Baht



# **Outlook and Strategic Plan**



## S-Curve strategy update and outlook

This year we expect to achieve at **Gross premium** >10% growth from year 2020. We can increase new treaties, collaborate with new partners and expand to new market.

## Maintaining **BAU profitability** and driving new growth thru **new S-Curve** and digitalization

**Exponential growth** 

Additional growth

#### **Base line growth**



Reactivate relationship with a non-active cedant



Proactive to fulfill the business gap with active cedants

New treaties

5

12

**9** Products launched

**11** Products Work In Progress

#### **New Partner**

#### **Digital broker**

**2** collaboration with product development sharing expected to launch in 2022.
 **Digital Partners**

**1** initiative project with Digital platform and 1 contract with ceding – Phase 1 operated. **PLRE's product** 

**1** Critical Illness product on process with ceding company

**New Market** CLMV Southeast Asia

#### Laos

1 New treaty in group life

#### Cambodia

**1HB product**launch in Q4/2021**1HS product**expected to launchin Q1/2022

Indonesia 1 collaboration with local reinsurer and 2 product proposed (CI128 and Diabetes)

2021

## **Service and Customer target Solutions**

This year alternative marketing team initiate the collaboration with several partners to obtain supplement service and customer target to be the value added service with our co-product development with client.



Get right potential prospects for our products with efficient cost thru Digital & Social Media channels



Sales & Acquisition Professional Call Center services




**Product Development** 

Global Reinsurers, Pharmaceutical, Hospitals, TeleMed, TPA



## **Outlook and New S-curve strategy – New Partner**

**New Partner** 



# THANK YOU! Q & A ?

